Forian Inc.: Bylaws amended and restated in their entirety (effective 2026-05-15).
“on May 15, 2026, the Company’s articles of incorporation and bylaws were each amended and restated in their entirety”
Forian Inc. — fact timeline
Source-grounded facts extracted from Forian Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Forian Inc.: Articles of incorporation amended and restated in their entirety (effective 2026-05-15).
“on May 15, 2026, the Company’s articles of incorporation and bylaws were each amended and restated in their entirety”
Forian Inc. underwent a change of control involving 2025 Acquisition Company, LLC for $2.17 per share in cash (closed 2026-05-15).
“the “ Offer ”) to acquire any and all of the issued and outstanding shares of common stock, par value $0.0001 per share of the Company (the “ Shares ”), at a purchase price of $2.17 per Share, in cash, without interest thereon and less any applicable tax withholding (the “ Offer Price ”). The Offer and related withdrawal rights expired as scheduled one”
Kristiina Vuori, M.D., Ph.D. resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Alyssa Varadhan resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Shahir Kassam-Adams resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Jennifer Hajj resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Adam Dublin resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Ian G. Banwell resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Mark J. Adler, M.D. resigned as director at Forian Inc..
“At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.”
Forian Inc. entered into Agreement and Plan of Merger with 2025 Acquisition Company, LLC and Bravo Merger Sub, Inc. (effective 2026-04-02).
“On April 2, 2026, Forian Inc., a Maryland corporation (the " Company " or " Forian "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), by and among the Company, 2025 Acquisition Company, LLC, a Delaware limited liability company (" Parent "), and Bravo Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Parent (" Purchaser ").”
Forian Inc. reported financial results for quarter and year ended December 31, 2025.
“On March 27, 2026, the Company issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.”
Forian Inc.: Company redomiciled from Delaware to Maryland via statutory conversion, with new charter and bylaws (effective 2026-01-09).
“The Redomiciliation was effective at 12:01 a.m. Eastern Time on January 9, 2026”
Forian Inc. engaged BDO USA, P.C. as its auditor.
“On June 26, 2025, Audit Committee approved the engagement of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm.”
Forian Inc. dismissed CBIZ CPAs P.C. as its auditor.
“On June 26, 2025, the Audit Committee of the Board of Directors of Forian, Inc. (the "Company") dismissed CBIZ CPAs P.C. ("CBIZ") as the Company's independent registered accounting firm.”
Edward Spaniel, Jr. resigned as Executive Vice President, General Counsel and Corporate Secretary at Forian Inc..
“On April 28, 2025, Edward Spaniel, Jr., Executive Vice President, General Counsel and Corporate Secretary of Forian Inc. (the “Company”), notified the Company of his resignation from all of his positions with the Company and its subsidiaries and affiliates, effective May 23, 2025.”
Forian Inc. engaged CBIZ CPAs P.C. as its auditor.
“engaged CBIZ as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025”
Forian Inc. dismissed Marcum LLP as its auditor.
“the Company dismissed Marcum as the Company’s independent registered accounting firm”
Forian Inc. reported that prior financial statements should not be relied upon.
“determined that the Company’s previously issued unaudited and audited consolidated financial statements as of and for each of the quarterly and year to date periods in 2023 and the quarterly period ended September 30, 2024 (the “Non-Reliance Periods”) should no longer be relied upon”
Forian Inc. reported the quarter ended March 31, 2024 results: revenue $4,877,378, net income $(1,212,615), EPS $(0.04).
“Results ● Forian delivered the following results for the first quarter of 2024: Three Months Ended March 31, Period- over- Period % Change 2024 Unaudited 2023 Unaudited Revenue $ 4,877,378 $ 4,870,387 0% Loss from continuing operations, net of tax $ (1,212,615 ) $ (2,248,799 ) 46% Income from discontinued operations, net of tax $ - $ 8,747,278 100% Net (loss) income”
Forian Inc. updated its Year ending December 31, 2024 guidance (initiated).
“Full Year 2024 Outlook Based on information as of March 28, 2024, the Company is sharing the following outlook for the year ending December 31, 2024: ● Revenue growth is expected to be in the range of 5% to 15% ● Adjusted EBITDA 1 margin is expected to be in the range of 8% to 12%”
Forian Inc. reported Twelve Months Ended December 31, 2023 results: revenue $20,481,330, net income $11,106,687, EPS $0.34.
“Full Year 2023 Financial Results Forian delivered the following results for the full year 2023: Twelve Months Ended December 31, 2023 Unaudited 2022 Unaudited Period-over- Period % Change Revenue $ 20,481,330 $ 16,418,141 25% Income (loss) from continuing operations, net of tax $ 1,733,430 $ (19,191,990 ) 109% Income (loss) from discontinued operations, net of tax $ 9,373,257 $ (6,779,981 ) 238% Net Income (loss) $ 11,106,687 $ (25,971,971 ) 143% Income (loss) from continuing operations, net of tax per share - diluted $ 0.05 $ (0.60 ) 108% Income (loss) from discontinued operations, net of tax per share - diluted $ 0.29 $ (0.21 ) 238% Income (loss) per share - diluted $ 0.34 $ (0.81 ) 142% Adjusted EBITDA (a non-GAAP financial measure defined below) $ 2,336,380 $ (6,707,809 ) 135%”
Forian Inc. reported Three Months Ended December 31, 2023 results: revenue $5,368,932, net income $1,388,943, EPS $0.04.
“Fourth Quarter 2023 Financial Results Forian delivered the following results for the fourth quarter of 2023: Three Months Ended December 31, 2023 Unaudited 2022 Unaudited Period-over- Period % Change Revenue $ 5,368,932 $ 4,969,673 8% Loss from continuing operations, net of tax $ (381,014 ) $ (1,900,105 ) 80% Income (loss) from discontinued operations, net of tax $ 1,769,957 $ (1,656,609 ) 207% Net Income (loss) $ 1,388,943 $ (3,556,714 ) 139% Loss from continuing operations, net of tax per share - diluted $ (0.01 ) $ (0.06 ) 83% Income (loss) from discontinued operations, net of tax per share - diluted $ 0.05 $ (0.05 ) 200% Income (loss) per share - diluted $ 0.04 $ (0.11 ) 136% Adjusted EBITDA (a non-GAAP financial measure defined below) $ 1,033,648 $ (425,434 ) 343%”
Forian Inc. amended Second Amendment to License Agreement with third-party data provider (the "Vendor") valued at License fee increased; revenue share fees removed; renewal terms added: one additional year (first) (effective 2023-12-20).
“On December 20, 2023, a subsidiary of Forian Inc., Medical Outcomes Research Analytics, LLC (together, the "Company"), entered into a second amendment (the "Amendment") to that certain License Agreement, dated of as of June 30, 2019 (the "License Agreement"), between the Company and a third-party data provider (the "Vendor") in order to, among other things, (a) provide for the Company's licensure of additional information assets; (b) modify the terms of use of such information assets; (c) extend the term of the License Agreement to include two additional renewal terms (the first for one additional year and the second for two additional years, each at the Company's election); and (d) modify the license fees relating to such information assets to increase the annual license fee and to remove all revenue share fees.”
Forian Inc. reported Third quarter 2023 results: revenue $5,348,469, net income $4,342,091, EPS $0.13.
“Forian delivered the following results for the third quarter of 2023: Three Months Ended September 30, Period- over- Period % Change 2023 Unaudited 2022 Unaudited Total revenue $ 5,348,469 $ 4,310,694 24% Income (loss) from continuing operations, net of tax $ 5,453,643 $ (2,966,053 ) 284% Loss from discontinued operations, net of tax $ (1,111,552 ) $ (2,161,571 )”
Forian Inc. reported the quarter ended June 30, 2023 results: revenue $4.9 million, net income $1.1 million, EPS $0.03 per share.
“● Forian delivered the following results for the second quarter of 2023: Three Months Ended June 30, Period- over- 2023 2022 Period % Unaudited Unaudited Change Total revenue $ 4,893,542 $ 3,602,913 36% Loss from continuing operations, net of tax $ (1,090,400 ) $ (4,008,132 ) 73% Loss from discontinued operations, net of tax $ (32,426 ) $ (1,425,413 ) 98% Net Loss”
Forian Inc. completed a disposition involving Vox Merger Sub, Inc. for approximately $5.9 million of cash proceeds, plus up to approximately $3.6 million in earnout payments (closed 2023-07-21).
“Medical Outcomes Research Analytics, LLC) held an equity interest merged with Vox Merger Sub, Inc. (the “Merger”). As a result of the Merger, Forian received approximately $5.9 million of cash proceeds in consideration of all of its equity interest in the customer. Forian may receive additional earnout payments in 2025 and 2026 in an aggregate amount of up to”
Forian Inc. shareholders approved Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“2. Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 . The appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified, with the following votes tabulated: For Against Abstain Broker Non-Vote 26,709,621 1,516 2,482 0”
Forian Inc. shareholders approved Election of three Class II Directors at the 2023-06-14 meeting.
“1. Election of three (3) Class II Directors . The following three (3) Class II director nominees were elected to serve as Class II directors of the Company, with the following votes tabulated: For Withheld Broker Non-Vote Mark J. Adler, M.D. 17,867,156 248,568 8,597,895 Jennifer Hajj 18,109,520 6,204 8,597,895 Shahir Kassam-Adams 17,766,385 349,339 8,597,895”
Forian Inc. reported quarter ended March 31, 2023 results: revenue $4,870,387, net income $6,498,479, EPS $0.19.
“● Forian delivered the following results for the first quarter of 2023: Three Months Ended March 31, Period- over- Period % Change 2023 Unaudited 2022 Unaudited Total revenue $ 4,870,387 $ 3,534,861 38% Loss from continuing operations, net of tax $ (2,248,799 ) $ (10,317,700 ) 78% Income (loss) from discontinued operations, net of tax $ 8,747,278 $ (1,536,388 )”
Forian Inc. reported the twelve months ended December 31, 2022 results: revenue $ 28,005,857, net income $ (25,971,971 ), EPS $ (0.81 ).
“Forian delivered the following results for the full year of 2022: Twelve Months Ended December 31, Period-over- 2022 2021 Period Unaudited Unaudited % Change Total revenues $ 28,005,857 $ 16,879,715 66% Net loss $ (25,971,971 ) $ (26,551,105 ) 2% Basic and diluted net loss per common share $ (0.81 ) $ (0.90 ) 10%”
Forian Inc. reported the three months ended December 31, 2022 results: revenue $ 7,903,992, net income $ (3,556,714 ), EPS $ (0.11 ).
“Forian delivered the following results for the fourth quarter of 2022: Three Months Ended December 31, Period-over- 2022 2021 Period Unaudited Unaudited % Change Total revenues $ 7,903,992 $ 5,749,366 37% Net loss $ (3,556,714 ) $ (8,048,790 ) 56% Basic and diluted net loss per common share $ (0.11 ) $ (0.22 ) 51%”
Forian Inc. completed a disposition involving BT Assets Group Inc. for $30 million (closed 2023-02-10).
“Buyer (the “Transaction”). Through the Transaction, the Company exited the cannabis software business. The total consideration paid by the Buyer under the Purchase Agreement is $30 million, subject to any working capital adjustments. The Buyer paid $20 million in cash at closing and is required to make twelve equal monthly payments totaling $10 million commencing”
Forian Inc. entered into License Agreement with BT Assets Group Inc. valued at Perpetual, world-wide, exclusive, royalty-free, transferrable and sublicensable license to certain U (effective 2023-02-10).
“The Company, Helix, BioTrack and the Buyer also entered into that certain License Agreement, dated February 10, 2023 (the “License Agreement”), pursuant to which the Company and its affiliates have been granted a perpetual (subject to certain conditions described below), world-wide, exclusive (subject to certain conditions as described in the License Agreement), royalty-free, transferrable and sublicensable license to certain U.S. transactional data processed by the point of sale software systems owned, licensed or operated by the Buyer and its affiliates.”
Forian Inc. entered into Stock Purchase Agreement with BT Assets Group Inc. valued at Total consideration of $30 million, $20 million cash at closing plus twelve equal monthly payments t (effective 2023-02-10).
“On February 10, 2023, Helix Technologies, Inc., a Delaware corporation (“Helix”) and a wholly owned subsidiary of Forian Inc. (the “Company”), completed the sale of 100% of the outstanding capital stock of its wholly owned subsidiary, Bio-Tech Medical Software, Inc., a Florida corporation (“BioTrack”), to BT Assets Group Inc., a Delaware corporation (“Buyer”) and a wholly owned subsidiary of Alleaves Inc., a Delaware corporation (“Alleaves”), pursuant to that certain Stock Purchase Agreement (the “Purchase Agreement”), dated February 10, 2023, by and among Helix, BioTrack and the Buyer (the “Transaction”).”
Max C. Wygod was appointed as Interim Chief Executive Officer and President at Forian Inc..
“Effective as of February 10 , 2023 , the Board appointed Max C. Wygod as interim Chief Executive Officer and President.”
Daniel Barton resigned as Chief Executive Officer, President and Class II Director at Forian Inc..
“On February 13, 2023, the Company announced that Daniel Barton resigned as the Company’s Chief Executive Officer and President and as a Class II member of the Board of Directors (the “Board”) effective February 10, 2023.”
Forian Inc. reported the quarter ended September 30, 2022 results: revenue $7,176,328, net income $(5,127,624), EPS $ (0.16 ). Guidance raised.
“Total revenues $ 7,176,328 $ 4,961,755 45% Net loss $ (5,127,624 ) $ (7,021,722 ) 27% Basic and diluted net loss per common share $ (0.16 ) $ (0.22 ) 29%”
Scott Ogur resigned as Director at Forian Inc..
“On December 28, 2021, Scott Ogur notified Max Wygod, Executive Chairman of the Board of Directors of Forian Inc. (the “Company”), of his intention to resign as a director of the Company, effective December 31, 2021.”
Clifford Farren changed role as Special Advisor at Forian Inc..
“Clifford Farren will transition from Chief Financial Officer to Special Advisor.”
Michael Vesey was appointed as Chief Financial Officer at Forian Inc..
“On September 1, 2021, the Company appointed Michael Vesey to the position of Chief Financial Officer, effective September 2, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.